OncoMatch/Clinical Trials/NCT06802835
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Is NCT06802835 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including EGFR Antibody and PD-1 antibody for nasopharyngeal cancinoma (npc).
Treatment: EGFR Antibody · PD-1 antibody · Gemcitabine, Cisplatin — This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Patients with nasopharyngeal carcinoma who have recurred/metastasized after initial treatment or radical treatment; At least 1 measurable lesion that meets RECIST 1.1 criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
WBC≥3.0×10^9/L, ANC≥1.5×10^9/L, PLT≥100×10^9/L, HGB≥90g/L (no blood transfusion and blood products within 14 days, no G-CSF and other hematopoietic stimulating factors are used to correct)
Kidney function
BUN and CRE≤1.5×ULN or endogenous creatinine clearance ≥60ml/min (Cockcroft-Gault formula)
Liver function
TBIL≤2.0×ULN, ALT, AST≤2.5×ULN
Cardiac function
The myocardial enzyme spectra were in the normal range; Uncontrolled cardiovascular disease: Grade II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms); Patients with grade III-IV cardiac insufficiency according to NYHA standards, or left ventricular ejection fraction (LVEF) <50% indicated by cardiac color ultrasound; Myocardial infarction within 1 year [excluded]
Blood routine examination standards should meet: WBC≥3.0×10^9/L, ANC≥1.5×10^9/L, PLT≥100×10^9/L, HGB≥90g/L (no blood transfusion and blood products within 14 days, no G-CSF and other hematopoietic stimulating factors are used to correct); Biochemical tests should meet the following criteria: TBIL≤2.0×ULN, ALT, AST≤2.5×ULN, BUN and CRE≤1.5×ULN or endogenous creatinine clearance ≥60ml/min (Cockcroft-Gault formula); Good coagulation function: defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN; If the subject is receiving anticoagulant therapy, as long as PT is within the intended range of anticoagulant drug use; The myocardial enzyme spectra were in the normal range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06802835 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages